Halozyme wins court order blocking Merck Keytruda in Europe
A Dutch court barred Merck from selling its subcutaneous Keytruda formulation in several European countries after Halozyme prevailed in a patent dispute.
Palanor Wire · composed from 3 outlets · every claim links to its sources
What happened
Halozyme won a patent fight against Merck. 13 A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. 123 The court ordered a halt to the manufacturing and marketing of the formulation in select European markets. 23
Why it matters
Merck suffered a setback in Europe over the new Keytruda formulation. 12
What to watch
Further legal developments in the patent dispute between Halozyme and Merck. 123 Whether Merck appeals or modifies its sales strategy for subcutaneous Keytruda in Europe. 13
Sources · 3
[1]STAT+: Merck suffers a setback in Europe over its new Keytruda formulation
STAT
[2]Halozyme wins court order to block Merck's injected Keytruda in select European markets reut.rs/4rRA8aY
Reuters · Bluesky
[3]Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
BioPharma Dive
Matched signals
Lattice signals Numen pinned to this story at publish time.
No matched signals on this story.
Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.
Upgrade →On X right now
Top engagement posts about this topic, ranked by likes + retweets + quotes.
No high-engagement X posts captured for this topic. Either the topic is too quiet or the upstream API was unavailable when this article published.
Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.
Upgrade →Your read
How did this article land?
Three sliders. Optional comment. Anonymous is fine.
Open to anyone. One response per reader.